UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

Clinical endocrinology (Oxford), 2005-11, Vol.63 (5), p.514-519

2005

Link zum Volltext

Verfügbarkeit prüfen

100 Rationale and Design for a Phase II Trial of Abobotulinumtoxina (Dysport) in the Management of Vulvodynia

Journal of sexual medicine, 2019-06, Vol.16 (6), p.S37-S37

2019

Link zum Volltext

Verfügbarkeit prüfen

Initial results from the international double-blind phase III study of Dysport® in the treatment of adults with upper limb spasticity

Annals of physical and rehabilitation medicine, 2014-05, Vol.57, p.e43-e44

2014

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design for a phase II trial of abobotulinumtoxinA (Dysport®) in the management of vulvodynia

Toxicon (Oxford), 2018-12, Vol.156, p.S40-S40

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide

The journal of clinical endocrinology and metabolism, 2000-04, Vol.85 (4), p.1487-1491

2000

Link zum Volltext

Verfügbarkeit prüfen

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

The journal of clinical endocrinology and metabolism, 1994-07, Vol.79 (1), p.145-151

1994

Link zum Volltext

Verfügbarkeit prüfen

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas

Clinical endocrinology (Oxford), 1994-03, Vol.40 (3), p.421-428

1994

Link zum Volltext

Verfügbarkeit prüfen

Treatment of carcinoid syndrome : A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance

Cancer, 2000-02, Vol.88 (4), p.770-776

2000

Link zum Volltext

Verfügbarkeit prüfen

Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995)

European journal of endocrinology, 1995-03, Vol.132 (3), p.320

1995

Link zum Volltext

Verfügbarkeit prüfen

Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans

British journal of clinical pharmacology, 1997, Vol.43 (1), p.65-70

1997

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide

The journal of clinical endocrinology and metabolism, 2000-04, Vol.85 (4), p.1487-1491

2000

Link zum Volltext

Verfügbarkeit prüfen

Traitement de l'acromégalie par un nouvel analogue de la somatostatine, le lanréotide à action prolongée

Annales d'endocrinologie, 1994, Vol.55 (6), p.261-269

1994

Link zum Volltext

Verfügbarkeit prüfen

Traitement de l'acromégalie par une forme à libération prolongée du lanréotide : un nouvel analogue de la somatostatine

La Presse médicale (1983), 1993, Vol.22 (11), p.526-531

1993

Link zum Volltext

Verfügbarkeit prüfen

Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans

British journal of clinical pharmacology, 1997-01, Vol.43 (1), p.65-70

1997

Link zum Volltext

Verfügbarkeit prüfen

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

The journal of clinical endocrinology and metabolism, 1994-07, Vol.79 (1), p.145-151

1994

Link zum Volltext

Verfügbarkeit prüfen

Treatment of acromegaly with a new slow release somatostatin analog, lanreotide

Annales d'endocrinologie, 1994, Vol.55 (6), p.261-269

1994

Link zum Volltext

Verfügbarkeit prüfen

Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog

La Presse médicale (1983), 1993-03, Vol.22 (11), p.526-531

1993

Link zum Volltext

Verfügbarkeit prüfen

An unusual infection after renal transplantation

Medical journal of Australia, 1986-11, Vol.145 (10), p.513-517

1986

Link zum Volltext

Verfügbarkeit prüfen

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(18)

Sprache

Englisch
(13)
Französisch
(5)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

100 Rationale and Design for a Phase II Trial of Abobotulinumtoxina (Dysport) in the Management of Vulvodynia

Initial results from the international double-blind phase III study of Dysport® in the treatment of adults with upper limb spasticity

Rationale and design for a phase II trial of abobotulinumtoxinA (Dysport®) in the management of vulvodynia

Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas

Treatment of carcinoid syndrome : A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance

Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995)

Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans

Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide

Traitement de l'acromégalie par un nouvel analogue de la somatostatine, le lanréotide à action prolongée

Traitement de l'acromégalie par une forme à libération prolongée du lanréotide : un nouvel analogue de la somatostatine

Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

Treatment of acromegaly with a new slow release somatostatin analog, lanreotide

Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog

An unusual infection after renal transplantation

Suchergebnisse filtern